For more than a century, CSL Behring has earned a reputation as an organization driven to care for patients with rare and serious diseases. We are a company known for keeping our promises – to ...

Here are a couple of strong ASX 200 shares that have been given buy ratings by brokers recently. Let's find out ...

The product was first developed by the Dutch biotechnology company uniQure. In 2020, CSL Behring paid $450 million to license the therapy. CSL Behring will be marketing the drug. Hemophilia B is ...

The UK's National Institute for Health and Care Excellence (NICE) has said it is minded not to recommend approval of CSL Behring and uniQure's Hemgenix gene therapy for haemophilia B as there is ...

Feel free to distribute or cite this material, but please credit OpenSecrets. For permission to reprint for commercial uses, such as textbooks, contact OpenSecrets: [email protected] ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus ...

CSL Ltd ( ASX: CSL) shares have faced a tough year. Whilst the broader market has extended to new highs in 2024, shares in ...

Analysts think these blue chips are top buys for investors right now. But why? The post 2 of the highest-quality blue chip ...

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The ...

It said: "In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for ...